8-K: Arcus Biosciences Reports Q4/FY25 Results, Casdatifan Progress

Arcus Biosciences reported its fourth-quarter and full-year 2025 financial results, highlighting strong casdatifan data and a cash runway extending into late 2028.

Summary

• Updated data for casdatifan in late-line kidney cancer demonstrated a median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort.
• At least two additional data presentations for casdatifan are expected in 2026, including updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer.
• Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026.
• Cash, cash equivalents, and marketable securities totaled $1.0 billion at year-end 2025, providing a cash runway until at least the second half of 2028.
• Revenues for the fourth quarter 2025 were $33 million, a decrease from $36 million in the same period in 2024.
• Full-year 2026 GAAP revenue is expected to be between $45 million to $55 million.
• Research and Development (R&D) Expenses increased to $121 million for Q4 2025, up from $111 million in Q4 2024, driven by late-stage development costs.
• Net Loss for the fourth quarter 2025 was $106 million, compared to $94 million for the same period in 2024.
• Enrollment was completed for PRISM-1, a Phase 3 trial of quemliclustat in 1L metastatic pancreatic ductal adenocarcinoma, in September 2025, with results expected in the first half of 2027.
• Arcus and Gilead are rapidly winding down activities related to the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies for domvanalimab plus zimberelimab.
• A futility analysis of STAR-121, a Phase 3 study evaluating domvanalimab plus zimberelimab and chemotherapy in 1L non-small cell lung cancer, will be conducted in the next couple of months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While casdatifan data and cash runway are strong positives, the increased net loss, decreased revenue, and winding down of TIGIT programs present financial and pipeline challenges.

Positives

• Updated casdatifan data in late-line ccRCC (100mg QD cohort) showed strong efficacy with a median PFS of 15.1 months and a cORR of 45%.
• Cash, cash equivalents, and marketable securities of $1.0 billion at year-end 2025 provide a robust financial position.
• Cash runway is projected to extend until at least the second half of 2028, offering significant operational stability.
• Casdatifan development is progressing with a planned Phase 3 study in the 1L metastatic setting by the end of 2026, targeting a potential $5 billion peak sales opportunity.
• The company is advancing an emerging inflammation and immunology (I&I) portfolio, with two programs expected to enter clinical development in 2026 and late 2026/early 2027.

Negatives

• Net loss increased to $106 million for Q4 2025, up from $94 million in Q4 2024.
• Total revenues decreased to $33 million for Q4 2025, down from $36 million in Q4 2024.
• Research and Development (R&D) expenses increased to $121 million for Q4 2025, compared to $111 million in Q4 2024.
• Arcus and Gilead are winding down the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies, indicating setbacks for the domvanalimab/zimberelimab program.
• A futility analysis for the Phase 3 STAR-121 study is pending, which could lead to further discontinuation of the domvanalimab/zimberelimab program.
• Partnership reimbursements decreased to $127 million for the full year 2025, compared to $165 million for 2024.

Risks

• Interim data may not be guarantees of future data or replicated in other studies evaluating casdatifan, including the Phase 3 PEAK-1 study.
• The unexpected emergence of adverse events or other undesirable side effects with casdatifan could impact its development.
• Risks are associated with manufacturing or supplying product for clinical trials evaluating casdatifan.
• Adverse data from toxicology studies could affect the ability to advance development candidates from immunology and inflammation programs.
• Uncertainties exist in timelines associated with the conduct of clinical studies and with respect to the regulatory approval process.
• Changes in the competitive landscape for programs could impact market potential.
• The inherent uncertainty associated with pharmaceutical product development and clinical trials poses a risk to future success.

Future Outlook

Arcus expects at least two casdatifan data readouts in 2026, including initial data in early-line settings. A Phase 3 study for casdatifan in 1L metastatic ccRCC is planned by the end of 2026. The company also anticipates advancing its first inflammation program and an oral small-molecule TNF inhibitor into clinical development in 2026 and late 2026/early 2027, respectively. Full-year 2026 GAAP revenue is projected to be between $45 million to $55 million, and R&D expenses are expected to decrease meaningfully, contingent on the results of the STAR-121 futility analysis.

Management Comments

• "This week's updated data at ASCO GU continue to validate casdatifan's profile as the best-in-class HIF-2a inhibitor and new potential standard-of-care therapy for ccRCC."
• "We are focused on rapidly enrolling PEAK-1, our Phase 3 study evaluating casdatifan plus cabozantinib in IO-experienced patients, as well as determining the optimal TKI-free casdatifan-based regimen for a registrational trial in the 1L setting by the end of the year."
• "Together, the IO-experienced and first line settings represent an over $5 billion peak sales opportunity for casdatifan."
• "We remain extremely well-positioned to execute on our casdatifan program and our emerging inflammation portfolio, with cash runway until at least the second half of 2028."

Industry Context

StockSavvy.ai notes that the oncology and immunology/inflammation sectors are highly competitive, with significant unmet needs. The focus on HIF-2a inhibition for ccRCC positions casdatifan against existing TKIs and immunotherapies, aiming for a "best-in-class" profile. The expansion into I&I with novel mechanisms (MRGPRX2 antagonist, selective TNFR1 inhibitor) reflects a broader industry trend of diversifying pipelines beyond oncology to leverage drug discovery capabilities. The winding down of certain TIGIT programs (domvanalimab) highlights the challenges and high attrition rates inherent in drug development, particularly in competitive areas like immuno-oncology where TIGIT has seen mixed results across the industry.

Comparison to Industry Standards

• The reported mPFS of 15.1 months and cORR of 45% for casdatifan in late-line ccRCC (100mg QD cohort) are competitive with or potentially superior to some existing therapies in similar settings. For instance, Merck's Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) showed a median PFS of 23.9 months and an ORR of 71% in first-line advanced RCC in the CLEAR study, while Pfizer's Inlyta (axitinib) monotherapy in advanced RCC showed a median PFS of 10.1 months. While not directly comparable due to different lines of therapy and combinations, casdatifan's monotherapy data in late-line settings appears promising.
• The $5 billion peak sales opportunity for casdatifan in IO-experienced and first-line settings suggests a significant market potential, aligning with the multi-billion dollar revenues generated by leading RCC drugs like Keytruda, Opdivo, and Cabometyx.

Stakeholder Impact

• Shareholders: Potential for increased value from casdatifan's strong clinical data and pipeline progression, but also risk from increased net loss and setbacks in the TIGIT program. The robust cash runway provides financial stability.
• Patients: Continued development of potential new therapies for kidney cancer (casdatifan) and pancreatic cancer (quemliclustat), as well as new treatments for inflammatory and autoimmune diseases.
• Employees: Continued focus on key programs, but the winding down of some studies might impact specific teams or roles.
• Partners (Gilead, Taiho, AstraZeneca): Ongoing collaborations with Gilead (though some programs are being wound down), Taiho's exercise of its option to casdatifan, and AstraZeneca's involvement in the eVOLVE-RCC02 study.

Next Steps

• Rapidly enroll PEAK-1, the Phase 3 study for casdatifan + cabozantinib in IO-experienced metastatic ccRCC.
• Determine optimal TKI-free casdatifan-based regimen for a registrational trial in the 1L setting by end of 2026.
• Present updated ORR and initial PFS data for casdatifan plus cabozantinib in IO-experienced setting at an investor event or medical conference (all patients will have had at least 12 months of follow-up).
• Present initial data from ARC-20 cohorts evaluating casdatifan in early-line settings, including the cohort evaluating casdatifan plus zimberelimab in 1L ccRCC, in the second half of 2026.
• Evaluate the potential of casdatifan in at least one additional combination in 1L ccRCC and in another tumor type in 2026.
• Conduct futility analysis of STAR-121 (domvanalimab plus zimberelimab and chemotherapy in 1L non-small cell lung cancer) in the next couple of months.
• Advance first inflammation program (oral MRGPRX2 antagonist) into clinical development in 2026.
• Initiate a first-in-human healthy volunteer study for the MRGPRX2 antagonist, followed quickly by a proof-of-concept study.
• Advance an oral small-molecule TNF inhibitor into the clinic in late 2026 or early 2027.
• Results from PRISM-1 (quemliclustat Phase 3 trial) are expected in the first half of 2027.

Key Dates

Recommendation

While the casdatifan data is promising and the cash runway is robust, the increased net loss, decreased revenue, and the winding down of multiple domvanalimab/zimberelimab studies introduce significant uncertainty and offset the positive developments. Investors should hold to observe the outcomes of the upcoming casdatifan data readouts and the futility analysis for STAR-121 before making further investment decisions.

Keywords

Arcus Biosciences, RCUS, casdatifan, HIF-2a inhibitor, kidney cancer, ccRCC, oncology, biopharmaceutical, clinical trial, Phase 3, quemliclustat, CD73 inhibitor, pancreatic cancer, domvanalimab, TIGIT, zimberelimab, PD-1, inflammation, autoimmune, MRGPRX2 antagonist, TNF inhibitor, financial results, pipeline update